Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About CFP Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About CFP Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Use of botulinum toxin A in management of children with cerebral palsy

Bat-Chen Friedman and Ran D. Goldman
Canadian Family Physician September 2011, 57 (9) 1006-1073;
Bat-Chen Friedman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question What is the role of intramuscular botulinum toxin injections in the management of spasticity and related morbidity in children with cerebral palsy?

Answer When botulinum toxin A is injected into the limbs of children with spastic paresis, it induces temporary reduction in muscle tone. It also promotes better motor function when used in combination with conservative treatments such as physiotherapy. Although there is a growing body of evidence for its effective and safe treatment, there is still a lack of consensus on dose, treatment regimens, and the best integration with other clinical modalities.

Cerebral palsy (CP) is a clinical syndrome characterized by a persistent disorder in motor control and posture, and results from nonprogressive brain damage.1 Cerebral palsy is the most common cause of physical disability in children, with a reported incidence of 2 to 2.5 per 1000 live births.1 Approximately 90% of affected children present with clinical symptoms of spastic paresis, a muscle-tone and muscle control–regulation disorder.2 Static muscle contractures and bony deformities develop slowly over time and are secondary consequences of spasticity. Children with CP require management by a multidisciplinary team to address each child’s particular needs. A treatment program usually focuses on the reduction or normalization of tone to prevent the development of secondary complications. The most common interventions are physiotherapy, use of orthotics, serial casting, electrical stimulation, and, more recently, the intramuscular injection of botulinum toxin type A (BtxA).

Botulinum toxin

Botulinum toxin type A is 1 of the 7 different serotypes of botulinum toxin (A to G) produced by the anaerobic bacterium Clostridium botulinum.3 Botulinum toxin type A selectively blocks the release of acetylcholine at the cholinergic nerve terminal, ensuring a temporary reduction in muscular activity in the injected muscles.3 The process is reversible and the return of synaptic function to the original neuromuscular junction takes approximately 90 days. The period of clinically useful relaxation is usually 12 to 16 weeks.4

Botulinum toxin type A injections were first given therapeutically for strabismus in the early 1980s.5 The treatment was adopted for other neurologic conditions, such as blepharospasm, cervical dystonia, and hemi-facial spasm. In 1993, Koman et al6 produced preliminary results of the first clinical trials using BtxA for spasticity in CP patients. The rationale for using BtxA for CP management was that the reduction of spasticity after BtxA injection opened a “therapeutic window” for interventions, enhancing both motor ability and functional skills and preventing contracture formation.7 Although at first BtxA was applied to one muscle at a time, it became apparent that many of the common limb dysfunctions and gait patterns in CP could be adequately treated only if several muscles were treated simultaneously.

Effectiveness of BtxA in CP management

In the past 2 decades, numerous trials have assessed the effectiveness of BtxA injections on motor function in children with CP.8–15 While several studies found statistically significant beneficial effects,8–10,13–15 others failed to demonstrate benefits.11,12 The use of distinct assessment tools and primary outcome measures, in addition to the diversity in clinical approaches, cointerventions, and subjects’ characteristics, partly accounts for the variability of the reports. Lack of consensus on recommended dose and diverse pharmacokinetic properties of commercially available BtxA preparations contribute to the challenge in interpreting the results of currently available literature.

In 2010, a Cochrane systematic review assessed the effectiveness of BtxA alone or in combination with occupational therapy for upper-limb treatment in children with CP. Ten randomized controlled trials (RCTs) were included. An analysis of data showed that a combination of BtxA and occupational therapy is more effective than occupational therapy alone in reducing impairment and improving activity-level outcomes, but not for improving quality of life or perceived self-competence. When BtxA was used alone there was moderate evidence that it was not effective.9

Several systematic reviews also analyzed the effectiveness of BtxA therapy in the management of lower-limb spasticity and gait in children with CP.10–12 In 2001, Boyd and Hays10 summarized results of 10 RCTs and found evidence for a moderate, dose-dependent treatment effect of BtxA on gait and lower-limb function. Koog and Min11 reviewed 15 RCTs and reported less-favourable results. When botulinum injection was compared with a non-sham control, it was effective in improving muscle tone, ankle range of motion, gross motor function, and gait speed; however, when sham injection was used as control, botulinum injection had affected gross motor function only when measured after 4 months. Koog and Min11 suggested that BtxA might not be as effective as commonly believed and might be overprescribed for CP patients. Recently, Ryll et al12 systematically reviewed 8 RCTs in order to assess treatment effects of BtxA on gait of children with CP. When compared with physiotherapy alone, adding BtxA treatment had a moderate positive effect after 2 to 24 weeks of follow-up. This effect was not demonstrated when BtxA treatment was compared with casting alone.

Age and long-term effects

Spasticity most commonly develops within the first few years of life in children with CP. Therefore, BtxA treatment is recommended at 2 to 6 years of age, when gait patterns and motor function are still flexible.8 Evidence relating to long-term outcome of treatment with BtxA is scarce. Desloovere et al13 demonstrated that BtxA injections delay and reduce the frequency of surgical procedures and result in a favourable gait pattern at 5 to 10 years of age. Similarly, Molenaers et al14 reported that BtxA treatment can delay and reduce the need for surgery in the follow-up of children with CP, provided that the treatment is started while gait patterns are still flexible. A recent prospective study on children with CP treated with BtxA included 57 children with a mean age of 6 years who were followed up for a year. Results demonstrated larger reduction in spasticity and better functional prognosis after BtxA injection in younger children. Botulinum toxin type A treatment also correlated with improvement in quality-of-life measures.15

Adverse effects

Botulinum toxin type A is considered to be one of the most potent poisons. However, when used in recommended doses, adverse events of BtxA are usually transient, mild, and local.16 Adverse events attributed to systemic spread of the toxin are uncommon and include flulike symptoms, generalized weakness, dysphagia, and subsequent aspiration caused by diminished airway protection.16 In 2008, the US Food and Drug Administration expressed concern about potential severe adverse effects (respiratory compromise and death) of BtxA based on reports of children treated for CP-associated limb spasticity.17 These concerns were contrary to previous safety-profile information.18 In a meta-analysis of safety with 20 RCTs and 882 participants, BtxA use was associated with respiratory tract infection, bronchitis, pharyngitis, muscle weakness, urinary incontinence, falls, seizures, fever, and unspecified pain. Two deaths were reported in one study and were found not to have causal relation to the toxin. The authors concluded that BtxA had a good short-term safety profile, but advocated careful monitoring, especially in children with more severe CP.19

Conclusion

Treatment of spastic-movement disorders associated with CP requires an interdisciplinary team approach with a range of conservative and surgical strategies. There is growing evidence that BtxA is effective in reducing spasticity and improving motor function when it is used in combination with other treatment measures. However, there is a lack of data about optimal dosing and injection schemes, and safety concerns demand strict monitoring of potential adverse effects, especially in children severely afflicted with CP.

Notes

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Dr Friedman is a member and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875–2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Stanley F,
    2. Blair E,
    3. Alberman E
    . Clinic in developmental medicine. No 151. London, UK: Mac Keith Press; 2000. Cerebral palsies: epidemiology and causal pathways; p. 22-39.
  2. ↵
    1. Beckung E,
    2. Carlsson G,
    3. Carlsdotter S,
    4. Uvebrant P
    . The natural history of gross motor development in children with cerebral palsy aged 1 to 15 years. Dev Med Child Neurol 2007;49(10):751-6.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Aoki KR,
    2. Guyer B
    . Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8(Suppl 5):21-9.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Aoki KR,
    2. Ranoux D,
    3. Wissel J
    . Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13(Suppl 4):10-9.
    OpenUrlPubMed
  5. ↵
    1. Scott AB,
    2. Rosenbaum A,
    3. Collins CC
    . Pharma-cologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 1973;12(12):924-7.
    OpenUrlFREE Full Text
  6. ↵
    1. Koman LA,
    2. Mooney JF 3rd.,
    3. Smith B,
    4. Goodman A,
    5. Mulvaney T
    . Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 1993;13(4):489-95.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Placzek R,
    2. Siebold D,
    3. Funk FJ
    . Development of treatment concepts for the use of botulinum toxin A in children with cerebral palsy. Toxins 2010;2(9):2258-71.doi:10.3390/toxins2092258
    OpenUrlPubMed
  8. ↵
    1. Molenaers G,
    2. Van Campenhout A,
    3. Fagard K,
    4. De Cat J,
    5. Desloovere K
    . The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop 2010;4(3):183-95. Epub 2010 Mar 18.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hoare BJ,
    2. Wallen MA,
    3. Imms C,
    4. Villanueva E,
    5. Rawicki HB,
    6. Carey L
    . Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010;(1):CD003469.
  10. ↵
    1. Boyd RN,
    2. Hays RM
    . Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Euro J Neurol 2001;8(Suppl 5):1-20.
    OpenUrl
  11. ↵
    1. Koog YH,
    2. Min BI
    . Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. Clin Rehabil 2010;24(8):685-700. Epub 2010 Jun 16.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ryll U,
    2. Bastiaenen C,
    3. De Bie R,
    4. Staal B
    . Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review. Dev Med Child Neurol 2011;53(3):210-6.doi:10.1111/j.1469-8749.2010.03890.x
    OpenUrlPubMed
  13. ↵
    1. Desloovere K,
    2. Molenaers G,
    3. De Cat J,
    4. Pauwels P,
    5. Van Campenhout A,
    6. Ortibus E,
    7. et al
    . Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol 2007;49(1):56-61.
    OpenUrlPubMed
  14. ↵
    1. Molenaers G,
    2. Desloovere K,
    3. Fabry G,
    4. De Cock P
    . The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 2006;88(1):161-70.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Coutinho dos Santos LH,
    2. Bufara Rodrigues DC,
    3. Simões de Assis TR,
    4. Bruck I
    . Effective results with botulinum toxin in cerebral palsy. Pediatr Neurol 2011;44(5):357-63.
    OpenUrlPubMed
  16. ↵
    1. O’Flaherty SJ,
    2. Janakan V,
    3. Morrow AM,
    4. Scheinberg AM,
    5. Waugh MC
    . Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol 2011;53(2):125-30.doi:10.1111/j.1469-8749.2010.03814.x
    OpenUrlCrossRefPubMed
  17. ↵
    FDA notifies public adverse reactions linked to botox use. Ongoing safety review of Botox, Botox Cosmetic and Myobloc [news release]. Silver Spring, MD; February 8, 2008. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116857.htm. Accessed 2011 Jun 24.
  18. ↵
    1. Goldstein EM
    . Safety of high-dose botulinum toxin type. A therapy for the treatment of pediatric spasticity. J Child Neurol 2006;21(3):189-92.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Albavera-Hernández C,
    2. Rodrıguez JM,
    3. Idrovo AJ
    . Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009;23(5):394-407. Epub 2009 Apr 23.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 57 (9)
Canadian Family Physician
Vol. 57, Issue 9
1 Sep 2011
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of botulinum toxin A in management of children with cerebral palsy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
Citation Tools
Use of botulinum toxin A in management of children with cerebral palsy
Bat-Chen Friedman, Ran D. Goldman
Canadian Family Physician Sep 2011, 57 (9) 1006-1073;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Use of botulinum toxin A in management of children with cerebral palsy
Bat-Chen Friedman, Ran D. Goldman
Canadian Family Physician Sep 2011, 57 (9) 1006-1073;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Botulinum toxin
    • Effectiveness of BtxA in CP management
    • Age and long-term effects
    • Adverse effects
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Scopus (11)
  • Google Scholar

More in this TOC Section

Practice

  • Contrasting current challenges from the Brazilian and Canadian national health systems
  • Pregnancy-related cardiovascular risk indicators
  • Putting the fun in fungi: toenail onychomycosis
Show more Practice

Child Health Update

  • Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy
  • Time-to-effect of fluoxetine in children with depression
  • Duct tape for warts in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2019 by The College of Family Physicians of Canada

Powered by HighWire